Professional role
Psychiatry Resident[1]
JE
Jacob Ellis
About
Jacob Ellis is conducting an observational study using time to discontinuation as an outcome measure for patients with treatment-resistant depression (TRD) who received IV ketamine or intranasal (IN) esketamine at the Mayo Clinic Depression Center from August 2017 to May 2024.
Research interests
long-term comparative efficacy between IV and IN ketamine · time to discontinuation as an outcome measure for patients with treatment-resistant depression (TRD) who received IV ketamine or intranasal (IN) esketamine
Research
Reviewed sources document long-term comparative efficacy between IV and IN ketamine and time to discontinuation as an outcome measure for patients with treatment-resistant depression (TRD) who received IV ketamine or intranasal (IN) esketamine. Publication attribution is still being resolved.
Explore researchEducation and career
Reviewed Sep 9, 2026Other education records
Education record
PGY-4[1]
Research
Research interests
long-term comparative efficacy between IV and IN ketamine[1]
Research interests
time to discontinuation as an outcome measure for patients with treatment-resistant depression (TRD) who received IV ketamine or intranasal (IN) esketamine[1]
Publications
0 attributed works. Counts reflect resolved authorship and may be incomplete.
No publications resolved yet.
Sources
Sources are listed once and connected to each accepted claim they support. Excerpts preserve the source language used in the review.
- [1]Department of Psychiatry and Psychology Researchers
7 source claims · Reviewed Sep 9, 2026
Biographical context: Jacob Ellis is conducting an observational study using time to discontinuation as an outcome measure for patients with treatment-resistant depression (TRD) who received IV ketamine or intranasal (IN) esketamine at the Mayo Clinic Depression Center from August 2017 to May 2024.
### Jacob Ellis, M.D., PGY-4 – Psychiatry Resident Mentor: Simon Kung, M.D. Jacob Ellis is conducting an observational study using time to discontinuation as an outcome measure for patients with treatment-resistant depression (TRD) who received IV ketamine or intranasal (IN) esketamine at the Mayo Clinic Depression Center from August 2017 to May 2024. This study aims to investigate the long-term comparative efficacy between IV and IN ketamine with an exploration of the reasons for discontinuation of treatment. This work has the potential to provide meaningful information when discussing outcomes with patients and can help inform individualized treatment planning and future research study designs. **Visual description:** Portrait photograph of a smiling man in a dark suit and tie against a gray background.
Degree: M.D.
### Jacob Ellis, M.D., PGY-4 – Psychiatry Resident Mentor: Simon Kung, M.D. Jacob Ellis is conducting an observational study using time to discontinuation as an outcome measure for patients with treatment-resistant depression (TRD) who received IV ketamine or intranasal (IN) esketamine at the Mayo Clinic Depression Center from August 2017 to May 2024. This study aims to investigate the long-term comparative efficacy between IV and IN ketamine with an exploration of the reasons for discontinuation of treatment. This work has the potential to provide meaningful information when discussing outcomes with patients and can help inform individualized treatment planning and future research study designs. **Visual description:** Portrait photograph of a smiling man in a dark suit and tie against a gray background.
Education record: PGY-4
### Jacob Ellis, M.D., PGY-4 – Psychiatry Resident Mentor: Simon Kung, M.D. Jacob Ellis is conducting an observational study using time to discontinuation as an outcome measure for patients with treatment-resistant depression (TRD) who received IV ketamine or intranasal (IN) esketamine at the Mayo Clinic Depression Center from August 2017 to May 2024. This study aims to investigate the long-term comparative efficacy between IV and IN ketamine with an exploration of the reasons for discontinuation of treatment. This work has the potential to provide meaningful information when discussing outcomes with patients and can help inform individualized treatment planning and future research study designs. **Visual description:** Portrait photograph of a smiling man in a dark suit and tie against a gray background.
Identity: Jacob Ellis
### Jacob Ellis, M.D., PGY-4 – Psychiatry Resident Mentor: Simon Kung, M.D. Jacob Ellis is conducting an observational study using time to discontinuation as an outcome measure for patients with treatment-resistant depression (TRD) who received IV ketamine or intranasal (IN) esketamine at the Mayo Clinic Depression Center from August 2017 to May 2024. This study aims to investigate the long-term comparative efficacy between IV and IN ketamine with an exploration of the reasons for discontinuation of treatment. This work has the potential to provide meaningful information when discussing outcomes with patients and can help inform individualized treatment planning and future research study designs. **Visual description:** Portrait photograph of a smiling man in a dark suit and tie against a gray background.
Professional role: Psychiatry Resident
### Jacob Ellis, M.D., PGY-4 – Psychiatry Resident Mentor: Simon Kung, M.D. Jacob Ellis is conducting an observational study using time to discontinuation as an outcome measure for patients with treatment-resistant depression (TRD) who received IV ketamine or intranasal (IN) esketamine at the Mayo Clinic Depression Center from August 2017 to May 2024. This study aims to investigate the long-term comparative efficacy between IV and IN ketamine with an exploration of the reasons for discontinuation of treatment. This work has the potential to provide meaningful information when discussing outcomes with patients and can help inform individualized treatment planning and future research study designs. **Visual description:** Portrait photograph of a smiling man in a dark suit and tie against a gray background.
Research interests: long-term comparative efficacy between IV and IN ketamine
### Jacob Ellis, M.D., PGY-4 – Psychiatry Resident Mentor: Simon Kung, M.D. Jacob Ellis is conducting an observational study using time to discontinuation as an outcome measure for patients with treatment-resistant depression (TRD) who received IV ketamine or intranasal (IN) esketamine at the Mayo Clinic Depression Center from August 2017 to May 2024. This study aims to investigate the long-term comparative efficacy between IV and IN ketamine with an exploration of the reasons for discontinuation of treatment. This work has the potential to provide meaningful information when discussing outcomes with patients and can help inform individualized treatment planning and future research study designs. **Visual description:** Portrait photograph of a smiling man in a dark suit and tie against a gray background.
Research interests: time to discontinuation as an outcome measure for patients with treatment-resistant depression (TRD) who received IV ketamine or intranasal (IN) esketamine
### Jacob Ellis, M.D., PGY-4 – Psychiatry Resident Mentor: Simon Kung, M.D. Jacob Ellis is conducting an observational study using time to discontinuation as an outcome measure for patients with treatment-resistant depression (TRD) who received IV ketamine or intranasal (IN) esketamine at the Mayo Clinic Depression Center from August 2017 to May 2024. This study aims to investigate the long-term comparative efficacy between IV and IN ketamine with an exploration of the reasons for discontinuation of treatment. This work has the potential to provide meaningful information when discussing outcomes with patients and can help inform individualized treatment planning and future research study designs. **Visual description:** Portrait photograph of a smiling man in a dark suit and tie against a gray background.